PDS Biotechnology Corporation

PDS Biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious disease. PDS Biotechnology has developed a novel immunostimulatory nanoparticle vaccine platform known as Versamune®. This multifunctional vector is capable of potent activation of immune cells without the side effects of traditional vaccines, efficiently delivering disease related antigen targets to the immune system and promoting antigen processing to present antigen appropriately to generate both strong prophylactic and therapeutic immune responses to disease. The Versamune® technology has been shown to be applicable to a wide range of vaccines for cancers and infectious diseases.